Cutaneous toxicity of anti-cancer therapies
Conditions
Interventions
trial group:nitroglycerin
Sponsors
Shanghai Jiao Tong University School of Biomedical Engineering
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patients voluntarily participated in the study and signed the informed consent form; 2. Patients >= 18 years old. 3. The patient was diagnosed as malignant tumor and was receiving anti-tumor drug treatment. 4. Patients with skin rash and / or hand foot syndrome related to anti-tumor drugs, with skin symptom score of 1 or above according to NCI CTCAE V5.0. 5. Patients can use external medication, and can complete the questionnaire survey. 6. Patients with ECoG score <= 2.
Exclusion criteria
Exclusion criteria: 1. The patient had skin adverse reactions (rash and / or hand foot syndrome) caused by non antineoplastic drugs before enrollment, and did not fully recover at 4 weeks before baseline. 2. Other topical drugs are being used in the corresponding parts of the patient's skin, and can not be stopped 7 days before the baseline. 3. The patient is suffering from other uncontrollable diseases, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, recent myocardial infarction, uncontrolled hypertension or hypotension, arrhythmia or psychosis, and other social conditions that may limit patient compliance with study requirements. 4. The patient had contraindications for the use of active ingredients of the trial drug, including severe anemia, elevated intracranial pressure, and known grade III hypertension. 5. The patient has other skin diseases that may affect the assessment. 6. The patient had used phosphodiesterase-5 inhibitors such as sildenafil, vardenafil, tadalafil, etc. within 7 days before baseline. 7. The patient had obvious laboratory abnormalities. 8. The patients were pregnant or lactating women. 9. The patient is a woman with fertility possibility and is not willing to take effective contraception two weeks before and during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NCI CTCAEv5.0; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS-pain;DLQI;HF-QoL; | — |
Countries
China
Contacts
Public ContactLina Tang
Shanghai Sixth People's Hospital
Outcome results
None listed